Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Payload diversification: a key step in the development of antibody–drug conjugates
Louise Conilh, Lenka Sadílková, Warren Viricel, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Antibody–drug conjugates come of age in oncology
Charles Dumontet, Janice M. Reichert, Peter D. Senter, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 8, pp. 641-661
Closed Access | Times Cited: 346
Clinical and translational advances in ovarian cancer therapy
Panagiotis A. Konstantinopoulos, Ursula A. Matulonis
Nature Cancer (2023) Vol. 4, Iss. 9, pp. 1239-1257
Closed Access | Times Cited: 116
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 558-576
Open Access | Times Cited: 114
Exploration of the antibody–drug conjugate clinical landscape
Heather Maecker, Vidya S. Jonnalagadda, Sunil Bhakta, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 54
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 54
Mechanisms of Resistance to Antibody–Drug Conjugates
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 52
Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 51
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 45
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 15
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer
Zohreh Najminejad, Fatemeh Dehghani, Yousef Mirzaei, et al.
Molecular Therapy (2023) Vol. 31, Iss. 7, pp. 1874-1903
Open Access | Times Cited: 35
ADCdb: the database of antibody–drug conjugates
Liteng Shen, Xiuna Sun, Zhen Chen, et al.
Nucleic Acids Research (2023) Vol. 52, Iss. D1, pp. D1097-D1109
Open Access | Times Cited: 31
The evolving landscape of antibody-drug conjugates in gynecologic cancers
Anthony W. Tolcher, Erika Hamilton, Robert L. Coleman
Cancer Treatment Reviews (2023) Vol. 116, pp. 102546-102546
Closed Access | Times Cited: 29
Development of antibody‐drug conjugates in cancer: Overview and prospects
Dan‐Yun Ruan, Hao‐Xiang Wu, Qi Meng, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 3-22
Open Access | Times Cited: 25
Therapeutic synthetic and natural materials for immunoengineering
Anna Slezak, Kevin Chang, Samir Hossainy, et al.
Chemical Society Reviews (2024) Vol. 53, Iss. 4, pp. 1789-1822
Open Access | Times Cited: 11
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
Ali Hussein Mer, Yousef Mirzaei, Fatemeh Misamogooe, et al.
Drug Delivery and Translational Research (2024) Vol. 14, Iss. 11, pp. 2963-2988
Closed Access | Times Cited: 10
Antibody-drug conjugates: Principles and opportunities
Zhi Xin Phuna, Prashanth Ashok Kumar, Elio Haroun, et al.
Life Sciences (2024) Vol. 347, pp. 122676-122676
Closed Access | Times Cited: 9
Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates
Tomohiro Watanabe, Naoko Arashida, Tomohiro Fujii, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 20, pp. 18124-18138
Open Access | Times Cited: 9
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
Mingxia Jiang, Qiao Li, Binghe Xu
Drug Resistance Updates (2024) Vol. 75, pp. 101086-101086
Closed Access | Times Cited: 8
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads
Meiyang Xi, Jingjing Zhu, Fengxia Zhang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116709-116709
Closed Access | Times Cited: 8
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
Domenico Izzo, Liliana Ascione, Lorenzo Guidi, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access | Times Cited: 1
Synthesis and Investigation of Peptide–Drug Conjugates Comprising Camptothecin and a Human Protein‐Derived Cell‐Penetrating Peptide
Isabella R. Palombi, Andrew M. White, Yasuko Koda, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top